FDA unveils transparency roadmap with plans for public NDA/BLA disclosures and inspection report publishing
read at raps ↗RegulatoryNeutral
The FDA published a transparency roadmap that outlines its FY 2026 achievements and sets out priorities for FY 2027.
One key priority is a proposal to require public disclosure of new drug applications (NDAs) and biologics license applications (BLAs) at the time they are filed.
The agency also plans to proactively publish all inspection reports, aiming to boost openness with the public and industry.
source
This writeup was produced by pharmadog from original reporting by raps.
Original headline: “Experts weigh in on FDA’s transparency roadmap”
read at raps ↗
comments(0)
5-min edit window · permanent after that